3. Duplicative Therapy

Concurrent administration of rifaximin with other approved antibiotic therapies for travelers’ diarrhea (i.e., azithromycin, fluoroquinolones, and trimethoprim-sulfamethoxazole) is not recommended as these combinations do not provide additional therapeutic benefit and may result in enhanced adverse events. Patient profiles containing concurrent prescriptions for rifaximin, and additional travelers’ diarrhea antibiotic therapy will be reviewed.